CJC-1295 is a synthetic peptide that mimics a natural hormone in your brain to stimulate the release of growth hormone. In clinical studies published in The Journal of Clinical Endocrinology & Metabolism, a single injection increased average growth hormone levels by 2- to 10-fold for six or more days and raised IGF-1 (a downstream marker of growth hormone activity) by 1.5- to 3-fold for up to two weeks. Those sustained elevations are what make CJC-1295 distinct from other growth hormone peptides, and they’re the reason it has attracted so much interest in anti-aging, body composition, and recovery circles.
How CJC-1295 Works in the Body
Your pituitary gland naturally releases growth hormone in pulses throughout the day, triggered by a signaling molecule called growth hormone-releasing hormone (GHRH). CJC-1295 is a lab-made analog of GHRH, meaning it fits into the same receptors on the pituitary and tells it to produce and release more growth hormone. The key difference from your body’s own GHRH is longevity: natural GHRH breaks down in minutes, while CJC-1295 is engineered to last far longer in circulation.
After injection, CJC-1295 binds to albumin, a protein abundant in your blood. This albumin binding acts like a slow-release mechanism, protecting the peptide from being cleared quickly and extending its active window from minutes to days. Research from Johns Hopkins found that CJC-1295 doesn’t just cause a temporary spike. It actually increases the amount of growth hormone messenger RNA in the pituitary and promotes the proliferation of somatotroph cells, the specialized cells responsible for making growth hormone. In other words, it appears to expand the pituitary’s capacity to produce growth hormone, not just force a one-time release.
The DAC vs. No-DAC Distinction
You’ll see CJC-1295 sold in two forms, and the difference matters significantly. The version “with DAC” (Drug Affinity Complex) includes a chemical modification that strengthens the albumin-binding effect, giving it a half-life of roughly 6 to 8 days. That means a single weekly injection can maintain elevated growth hormone signaling for most of the week. The version “without DAC,” sometimes called Modified GRF 1-29, has a much shorter half-life of around 30 minutes to 2 hours.
The practical difference comes down to how growth hormone gets released. The no-DAC version produces a sharp, defined pulse of growth hormone that more closely mimics the body’s natural rhythm. The DAC version creates a more sustained, continuous elevation. Some practitioners prefer the no-DAC form specifically because those discrete pulses may better preserve the body’s normal feedback loops. The DAC version appeals to people who want fewer injections and a simpler protocol.
Why It’s Often Paired With Ipamorelin
CJC-1295 is frequently combined with another peptide called Ipamorelin, and the pairing isn’t arbitrary. These two compounds stimulate growth hormone release through completely different pathways. CJC-1295 works on the GHRH receptor, essentially telling the pituitary “make more growth hormone.” Ipamorelin works on a separate receptor (the ghrelin receptor), which amplifies the size of each growth hormone pulse. When you activate both pathways simultaneously, the resulting growth hormone release is larger than what either peptide achieves alone.
Combination products are typically supplied as pre-mixed formulations. The standard protocol calls for injections at bedtime on an empty stomach, five days per week, with two days off. Bedtime dosing is intentional: your largest natural growth hormone pulse happens during deep sleep, so the peptides amplify a process that’s already ramping up.
What Effects Users Report
Growth hormone influences a wide range of tissues, so the downstream effects of CJC-1295 touch multiple systems. Elevated growth hormone and IGF-1 promote fat metabolism, particularly the breakdown of visceral fat around organs. They also support muscle protein synthesis, collagen production in skin and joints, and deeper sleep quality. Many users report improved body composition over weeks to months, with gradual fat loss and modest increases in lean mass, even without dramatic changes to diet or exercise.
Recovery from exercise or injury is another commonly cited benefit. Growth hormone accelerates tissue repair, which is why it plays such a central role during sleep. People using CJC-1295 often notice reduced soreness and faster bounce-back between training sessions. Skin quality improvements, including better hydration and elasticity, tend to emerge over longer timeframes as collagen turnover increases.
It’s worth noting that these effects develop gradually. Unlike synthetic growth hormone injections that deliver a pharmacological dose all at once, CJC-1295 works by amplifying your own production. The timeline for noticeable changes is typically weeks to months rather than days.
Side Effects and Risks
The most common side effects are injection site reactions: temporary pain, swelling, and hardness at the injection spot, sometimes with localized hives. Beyond the injection site, reported side effects include flu-like symptoms, headaches, irritability, anxiety, nausea, and hives elsewhere on the body. The FDA has also flagged more serious adverse events, including increased heart rate and systemic vasodilatory reactions (a sudden drop in blood pressure caused by blood vessels widening).
Flushing and a head rush shortly after injection are frequently mentioned in user communities, particularly with the no-DAC version. These effects are typically brief, lasting a few minutes, but can be uncomfortable. Timing injections at bedtime helps, since you’re lying down and heading to sleep anyway.
The broader concern with any peptide that raises growth hormone chronically is its potential effect on insulin sensitivity. Growth hormone and insulin have an antagonistic relationship. Sustained elevations in growth hormone can reduce how effectively your cells respond to insulin, which is relevant for anyone with prediabetes or metabolic concerns.
Current Regulatory Status
CJC-1295 is not approved by the FDA for any medical use. It has been available through compounding pharmacies, which custom-prepare medications not commercially manufactured. However, the FDA has raised concerns about compounded CJC-1295 products, citing risks of immunogenicity (the body mounting an immune response against the peptide), challenges with ensuring purity, and limited clinical data supporting its safety profile.
CJC-1295 appeared on an FDA list of bulk drug substances that may present significant safety risks for compounding. The substance was ultimately listed in the “nominated but withdrawn” category, meaning it was put forward for evaluation but pulled from the formal review process. The regulatory landscape for compounded peptides has been shifting rapidly, and availability through compounding pharmacies varies by state and may change with new FDA guidance.
Timing and Dosing Protocols
For the no-DAC version (with or without Ipamorelin), the typical protocol involves subcutaneous injections at bedtime, five nights per week. Dosing on an empty stomach is considered important, ideally at least two to three hours after your last meal. Food, especially carbohydrates, triggers insulin release, which blunts the growth hormone response. A fasted state removes that brake and allows for a larger growth hormone pulse.
The DAC version simplifies the schedule to a single injection of around 600 micrograms once per week, though the same fasted-state guidance applies. Some protocols cycle the peptide, using it for several weeks followed by a break, while others run it continuously. There’s no consensus from clinical trials on optimal cycling because the available human data comes from short-term studies rather than long-term use trials.